nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

20.03.2021 | Review Article

Anticancer potential of metformin: focusing on gastrointestinal cancers

verfasst von: Mohammad rafi Khezri, Hassan Malekinejad, Naime Majidi-Zolbanin, Morteza Ghasemnejad-Berenji

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Gastrointestinal cancers are one of the most common types of cancer that have high annual mortality; therefore, identification and introduction of safe drugs in the control and prevention of these cancers are of particular importance. Metformin, a lipophilic biguanide, is the most commonly prescribed agent for type 2 diabetes management. In addition to its great effects on lowering the blood glucose concentrations, the anti-cancer properties of this drug have been reported in many types of cancers such as gastrointestinal cancers. Hence the effects of this agent as a safe drug on the reduction of gastrointestinal cancer risk and suppression of these types of cancers have been studied in different clinical trials. Furthermore, the proposed mechanisms of metformin in preventing the growth of these cancers have been investigated in several studies. In this review, we discuss recent advances in elucidating the molecular mechanisms that are relevant for metformin use in gastrointestinal cancer treatment.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S (2012) Cancer treatment and survivorship statistics 2012. CA Cancer J Clin 62(4):220–241PubMedCrossRef

Society AC (2014) Cancer facts and figures 204. Am Cancer Soc 4:10–40

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018) Global cancer observatory: cancer today. Lyon France Internat Agency Res Cancer 33:190–230

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304–1305PubMedPubMedCentralCrossRef

Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, DePinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754):1642–1646PubMedPubMedCentralCrossRef

Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606–619PubMedCrossRef

Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, Evangelisti C (2012) The emerging multiple roles of nuclear. Akt Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res 183(12):2168–2178

Pfeffer CM, Singh AT (2018) Apoptosis: a target for anticancer therapy. Int J Mol Sci 19(2):448PubMedCentralCrossRef

Tang C, Lu Y-H, Xie J-H, Wang F, Zou J-N, Yang J-S, Xing Y-Y, Xi T (2009) Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis. Anticancer Drugs 20(4):249–258PubMedCrossRef

10.

Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392):1318–1321PubMedCrossRef

11.

Masuyama N, Oishi K, Mori Y, Ueno T, Takahama Y, Gotoh Y (2001) Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis. J Biol Chem 276(35):32799–32805PubMedCrossRef

12.

Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857–868PubMedCrossRef

13.

Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231–241PubMedCrossRef

14.

Wilson BE, Mochon E, Boxer LM (1996) Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16(10):5546–5556PubMedPubMedCentralCrossRef

15.

Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE-B (2000) Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275(15):10761–10766PubMedCrossRef

16.

Du K, Montminy M (1998) CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273(49):32377–32379PubMedCrossRef

17.

Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Ki M, Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H (2001) ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2(3):222–228PubMedPubMedCentralCrossRef

18.

Yamamoto K, Ichijo H, Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 19(12):8469–8478PubMedPubMedCentralCrossRef

19.

Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou J-C (1997) Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 272(40):25238–25242PubMedCrossRef

20.

Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui TN, Xiang J, Lin A (2004) JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 13(3):329–340PubMedCrossRef

21.

An D, Kewalramani G, Chan J, Qi D, Ghosh S, Pulinilkunnil T, Abrahani A, Innis S, Rodrigues B (2006) Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia 49(9):2174–2184PubMedCrossRef

22.

Jang JH, Song IH, Sung EG, Lee TJ, Kim JY (2018) Metformin-induced apoptosis facilitates degradation of the cellular caspase 8 (FLICE)-like inhibitory protein through a caspase-dependent pathway in human renal cell carcinoma A498 cells. Oncol Lett 16(2):2030–2038PubMedPubMedCentral

23.

Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB, Khaper N (2014) Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS ONE 9:5CrossRef

24.

Wu N, Gu C, Gu H, Hu H, Han Y, Li Q (2011) Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 58(6):482PubMedCrossRef

25.

Dawson D, Volpert O, Gillis P, Crawford S, Xu H-J, Benedict W, Bouck N (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425):245–248PubMedCrossRef

26.

Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A (2011) SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31(6):1121–1133PubMedPubMedCentralCrossRef

27.

Hayes JD, Chowdhry S, Dinkova-Kostova AT, Sutherland C (2015) Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of β-TrCP and GSK-3. Biochem Soc Trans 43(4):611–620PubMedCrossRef

28.

Inoki K, Corradetti MN, Guan K-L (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37(1):19–24PubMedCrossRef

29.

El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ (2003) Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Can Res 63(17):5173–5177

30.

Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, Hoxhaj G, Saghatelian A, Shaw RJ, Manning BD (2017) Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab 25(2):463–471PubMedPubMedCentralCrossRef

31.

Wang J, Li G, Wang Y, Tang S, Sun X, Feng X, Li Y, Bao G, Li P, Mao X (2015) Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis. Oncotarget 6(42):44579PubMedPubMedCentralCrossRef

32.

Zhou X, Chen J, Yi G, Deng M, Liu H, Liang M, Shi B, Fu X, Chen Y, Chen L (2016) Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget 7(1):873PubMedCrossRef

33.

Yu C, Jiao Y, Xue J, Zhang Q, Yang H, Xing L, Chen G, Wu J, Zhang S, Zhu W (2017) Metformin sensitizes non-small cell lung cancer cells to an epigallocatechin-3-gallate (EGCG) treatment by suppressing the Nrf2/HO-1 signaling pathway. Int J Biol Sci 13(12):1560PubMedPubMedCentralCrossRef

34.

Urpilainen E, Kangaskokko J, Puistola U, Karihtala P (2019) Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes. Tumor Biol 41(1):1010428318815413CrossRef

35.

Vlotides G, Tanyeri A, Spampatti M, Zitzmann K, Chourdakis M, Spöttl G, Maurer J, Nölting S, Göke B, Auernhammer CJ (2014) Anticancer effects of metformin on neuroendocrine tumor cells in vitro. Hormones 13(4):498–508PubMed

36.

Li H, Zuo S, He Z, Yang Y, Pasha Z, Wang Y, Xu M (2010) Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. Am J Physiol-Heart Circulatory Physiol 299(6):H1772–H1781CrossRef

37.

Boidot R, Vegran F, Jacob D, Chevrier S, Cadouot M, Feron O, Solary E, Lizard-Nacol S (2010) The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene 29(17):2577–2584PubMedCrossRef

38.

Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S (2006) Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood 107(3):907–915PubMedPubMedCentralCrossRef

39.

Wang J-C, Li G-Y, Li P-P, Sun X, Li W-M, Li Y, Lu S-Y, Liu P-J (2017) Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion. Oncotarget 8(43):73892PubMedPubMedCentralCrossRef

40.

Dayanir V, Meyer RD, Lashkari K, Rahimi N (2001) Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 276(21):17686–17692PubMedCrossRef

41.

Li X, Yang Z, Song W, Zhou L, Li Q, Tao K, Zhou J, Wang X, Zheng Z, You N (2013) Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)-2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol 43(3):793–802PubMedCrossRef

42.

Esfahanian N, Shakiba Y, Nikbin B, Soraya H, Maleki-Dizaji N, Ghazi-Khansari M, Garjani A (2012) Effect of metformin on the proliferation, migration, and MMP-2 and-9 expression of human umbilical vein endothelial cells. Mole Med Rep 5(4):1068–1074CrossRef

43.

Jeddi F, Soozangar N, Sadeghi MR, Somi MH, Shirmohamadi M, Eftekhar-Sadat A-T, Samadi N (2018) Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer. Biomed Pharmacother 97:286–292PubMedCrossRef

44.

Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Ki K, Kim BH, Kim SK, Song GY (2011) Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162(5):1096–1108PubMedPubMedCentralCrossRef

45.

Hayden A, Douglas J, Sommerlad M, Andrews L, Gould K, Hussain S, Thomas GJ, Packham G, Crabb SJ (2014) The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. In: urologic oncology: seminars and original investigations. Elsevier

46.

Selvakumaran M, Lin H-K, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9(6):1791–1798PubMed

47.

Han J, Sabbatini P, Perez D, Rao L, Modha D, White E (1996) The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10(4):461–477PubMedCrossRef

48.

Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296–299PubMedCrossRef

49.

Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420(1):25–27PubMedCrossRef

50.

Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387(6630):299–303PubMedCrossRef

51.

Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, Margeli M, Felip E, Méndez P (2004) Molecular predictors of response to chemotherapy in lung cancer In: Seminars in oncology. ElsevierCrossRef

52.

Chu G (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269(2):787–790PubMedCrossRef

53.

Liang Y, Lin S-Y, Brunicardi FC, Goss J, Li K (2009) DNA damage response pathways in tumor suppression and cancer treatment. World J Surg 33(4):661–666PubMedCrossRef

54.

Toledo LI, Murga M, Fernandez-Capetillo O (2011) Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol 5(4):368–373PubMedPubMedCentralCrossRef

55.

Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, Mencalha AL, Lopes NMD, Luiz RC, Cecchini R (2019) Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Scientif Rep 9(1):1–11

56.

Qiang P, Shao Y, Sun Y, Zhang J, Chen L (2019) Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway. Eur Rev Med Pharmacol Sci 23(4):1778–1785PubMed

57.

Riaz MA, Sak A, Erol YB, Groneberg M, Thomale J, Stuschke M (2019) Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities. Scientif Rep 9(1):1–16

58.

Kim S-H, Kim S-C, Ku J-L (2017) Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells. Oncotarget 8(34):56546PubMedPubMedCentralCrossRef

59.

O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402CrossRef

60.

Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2):647–658PubMedCrossRef

61.

Deng Y, Ma W (2018) Metformin inhibits HaCaT cell viability via the miR-21/PTEN/Akt signaling pathway. Molecular Med Rep 17(3):4062–4066

62.

Luo M, Tan X, Mu L, Luo Y, Li R, Deng X, Chen N, Ren M, Li Y, Wang L (2017) MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway. Scientif Rep 7:43427CrossRef

63.

Ye T, Yang M, Huang D, Wang X, Xue B, Tian N, Xu X, Bao L, Hu H, Lv T (2019) MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res 38(1):55PubMedPubMedCentralCrossRef

64.

Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Chu Y (2011) MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 7(6):805PubMedPubMedCentralCrossRef

65.

Dong J, Peng H, Yang X, Wu W, Zhao Y, Chen D, Chen L, Liu J (2020) Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells. Anticancer Drugs 31(4):345PubMedPubMedCentralCrossRef

66.

Welch C, Chen Y, Stallings R (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26(34):5017–5022PubMedCrossRef

67.

Kumar B, Yadav A, Lang J, Teknos TN, Kumar P (2012) Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS ONE 7(5):9CrossRef

68.

Xie W, Wang L, Sheng H, Qiu J, Zhang D, Zhang L, Yang F, Tang D, Zhang K (2017) Metformin induces growth inhibition and cell cycle arrest by upregulating microRNA34a in renal cancer cells. Med Sci Monitor Internat Med J Exp Clin Res 23:29

69.

Do MT, Kim HG, Choi JH, Jeong HG (2014) Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radical Biol Med 74:21–34CrossRef

70.

Chai Z-T, Kong J, Zhu X-D, Zhang Y-Y, Lu L, Zhou J-M, Wang L-R, Zhang K-Z, Zhang Q-B, Ao J-Y (2013) MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma. PLoS ONE 8(10):8CrossRef

71.

Gao X-M, Zhu Y, Li J-H, Wang X-Y, Zhang X-F, Yi C-H, Yang X (2018) microRNA-26a induces a mitochondrial apoptosis mediated by p53 through targeting to inhibit Mcl1 in human hepatocellular carcinoma. Oncotargets Therapy 11:2227PubMedPubMedCentralCrossRef

72.

Li W, Yuan Y, Huang L, Qiao M, Zhang Y (2012) Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 96(2):187–195PubMedCrossRef

73.

Feng S, Cong S, Zhang X, Bao X, Wang W, Li H, Wang Z, Wang G, Xu J, Du B (2011) MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res 39(15):6669–6678PubMedPubMedCentralCrossRef

74.

Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, Wang J (2014) MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene 33(46):5332–5340PubMedCrossRef

75.

Wang Y, Dai W, Chu X, Yang B, Zhao M, Ye S (2013) Metformin inhibits lung cancer cells proliferation through repressing microRNA-222. Biotechnol lett 35(12):8CrossRef

76.

Cioce M, Valerio M, Casadei L, Pulito C, Sacconi A, Mori F, Biagioni F, Manetti C, Muti P, Strano S (2014) Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget 5(12):4129PubMedPubMedCentralCrossRef

77.

Jiang X, Ma N, Wang D, Li F, He R, Li D, Zhao R, Zhou Q, Wang Y, Zhang F (2015) Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget 6(5):3178PubMedCrossRef

78.

Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N (1987) Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 329(6140):630–632PubMedCrossRef

79.

Lai K-C, Liu C-J, Lin T-J, Mar A-C, Wang H-H, Chen C-W, Hong Z-X, Lee T-C (2016) Blocking TNF-α inhibits angiogenesis and growth of IFIT2-depleted metastatic oral squamous cell carcinoma cells. Cancer Lett 370(2):207–215PubMedCrossRef

80.

Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T (1998) Regulation of matrix metalloproteinases (MMP-2,-3,-9, and-13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139(3):1338–1345PubMedCrossRef

81.

Chow MT, Luster AD (2014) Chemokines in cancer. Cancer Immunol Res 2(12):1125–1131PubMedPubMedCentralCrossRef

82.

Liu T, Zhang L, Joo D, Sun S-C (2017) NF-κB signaling in inflammation. Signal Trans Target Therapy 2(1):1–9

83.

Liu Y-L, Yu J-M, Song X-R, Wang X-W, Xing L-G, Gao B-B (2006) Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther 5(10):1320–1326PubMedCrossRef

84.

Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H (2003) NF-κ B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278(24):21631–21638PubMedCrossRef

85.

Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase. Nature 401(6748):82–85PubMedCrossRef

86.

DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M (1997) A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 388(6642):548–554PubMedCrossRef

87.

Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) The IkB kinase complex (IKK) contains two kinase subunits, IKKa and IKKb, necessary for IkB phosphorylation and NF-kB activation. Cell 91(2):243–252PubMedCrossRef

88.

Tsuji G, Hashimoto-Hachiya A, Yen VH, Takemura M, Yumine A, Furue K, Furue M, Nakahara T (2020) Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis. Cell Death Discov 6(1):1–11CrossRef

89.

Ye J, Zhu N, Sun R, Liao W, Fan S, Shi F, Lin H, Jiang S, Ying Y (2018) Metformin inhibits chemokine expression through the AMPK/NF-κB signaling pathway. J Interferon Cytokine Res 38(9):363–369PubMedCrossRef

90.

Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D (2013) STAT inhibitors for cancer therapy. J Hematol Oncol 6(1):90PubMedPubMedCentralCrossRef

91.

Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8(5):409–422PubMedCrossRef

92.

Deng X-S, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD (2012) Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11(2):367–376PubMedCrossRef

93.

Yang Y, Jin G, Liu H, Liu K, Zhao J, Chen X, Wang D, Bai R, Li X, Jang Y (2017) Metformin inhibits esophageal squamous cell carcinoma-induced angiogenesis by suppressing JAK/STAT3 signaling pathway. Oncotarget 8(43):74673PubMedPubMedCentralCrossRef

94.

Cheung KS, Chan EW, Wong AY, Chen L, Seto WK, Wong IC, Leung WK (2019) Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication. JNCI J Nat Cancer Instit 111(5):484–489CrossRef

95.

Lee C-k, Jung M, Jung I, Heo SJ, Jeong YH, An JY, Kim H-I, Cheong J-H, Hyung WJ, Noh SH (2016) Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg 263(1):96–102PubMedCrossRef

96.

Jun K-H, Lee JE, Kim SH, Jung J-H, Choi HJ, Kim YI, Chin H-M, Yang S-H (2015) Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. Oncol Rep 34(4):2047–2053PubMedCrossRef

97.

Smyth E, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D (2016) Gastric cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up. Ann oncol 27(5):38–49CrossRef

98.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111PubMedCrossRef

99.

Courtois S, Durán RV, Giraud J, Sifré E, Izotte J, Mégraud F, Lehours P, Varon C, Bessède E (2017) Metformin targets gastric cancer stem cells. Eur J Cancer 84:193–201PubMedCrossRef

100.

Andersson G, Wennersten C, Borgquist S, Jirström K (2016) Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study. Biol Sex Differences 7(1):66CrossRef

101.

Wang Z, Lai S-t, Xie L, Zhao J-d, Ma N-y, Zhu J, Ren Z-g, Jiang G-l (2014) Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 106(1):19–26PubMedCrossRef

102.

Xin W, Fang L, Fang Q, Zheng X, Huang P (2018) Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: a meta-analysis. Mole Clin Oncol 8(3):483–488

103.

Li D, Yeung SCJ, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137(2):482–488PubMedCrossRef

104.

Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18(10):2905–2912PubMedPubMedCentralCrossRef

105.

Spillane S, Bennett K, Sharp L, Barron TI (2013) A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol Prev Biomark 22(8):1364–1373CrossRef

106.

Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim WH (2012) Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Dig Liver Dis 44(12):1042–1047PubMedCrossRef

107.

Tseng C-H (2017) Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus. Oncotarget 8(12):18802PubMedCrossRef

108.

Ma S, Zheng Y, Xiao Y, Zhou P, Tan H (2017) Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine 96(19):9CrossRef

109.

Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, Chen M, Yang J, Zou X (2015) Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res 5(4):1423PubMedPubMedCentral

110.

Han G, Gong H, Wang Y, Guo S, Liu K (2015) AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 16(1):77–87PubMedCrossRef

111.

Sekino N, Kano M, Matsumoto Y, Sakata H, Murakami K, Toyozumi T, Otsuka R, Yokoyama M, Shiraishi T, Okada K (2018) The antitumor effects of metformin on gastric cancer in vitro and on peritoneal metastasis. Anticancer Res 38(11):6263–6269PubMedCrossRef

112.

Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV (2013) Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Trans Oncol 6(6):649–647CrossRef

113.

Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013) Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE 8(2):9CrossRef

114.

Nair V, Pathi S, Jutooru I, Sreevalsan S, Basha R, Abdelrahim M, Samudio I, Safe S (2013) Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 34(12):2870–2879PubMedPubMedCentralCrossRef

115.

Tan X-L, Bhattacharyya KK, Dutta SK, Bamlet WR, Rabe KG, Wang E, Smyrk TC, Oberg AL, Petersen GM, Mukhopadhyay D (2015) Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. Pancreas 44(4):636PubMedPubMedCentralCrossRef

116.

DePeralta DK, Wei L, Ghoshal S, Schmidt B, Lauwers GY, Lanuti M, Chung RT, Tanabe KK, Fuchs BC (2016) Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 122(8):1216–1227PubMedCrossRef

117.

Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S (2014) Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 45(1):322–332PubMedCrossRef

118.

Tsai C-C, Chuang T-W, Chen L-J, Niu H-S, Chung K-M, Cheng J-T, Lin K-C (2015) Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells. World J Gastroenterol WJG 21(14):4169PubMedCrossRef

119.

Feng Y-H, Wu C-L, Shiau A-L, Lee J-C, Chang J-G, Lu P-J, Tung C-L, Feng L-Y, Huang W-T, Tsao C-J (2012) MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med 29(5):920–926PubMed

120.

Kobayashi M, Kato K, Iwama H, Fujihara S, Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J (2013) Antitumor effect of metformin in esophageal cancer: in vitro study. Int J Oncol 42(2):517–524PubMedCrossRef

121.

Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S (2014) Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol 45(2):567–574PubMedPubMedCentralCrossRef

122.

Fujihara S, Kato K, Morishita A, Iwama H, Nishioka T, Chiyo T, Nishiyama N, Miyoshi H, Kobayashi M, Kobara H (2015) Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. Int J Oncol 46(5):2172–2180PubMedCrossRef

123.

Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung S-C, Zhang H (2014) Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis 5(2):e1088–e1088PubMedPubMedCentralCrossRef

124.

Wang F, Ding X, Wang T, Shan Z, Wang J, Wu S, Chi Y, Zhang Y, Lv Z, Wang L (2017) Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin. PLoS ONE 12(4):12–23

125.

Shafaee A, Islamian JP, Zarei D, Mohammadi M, Nejati-Koshki K, Farajollahi A, Aghamiri SMR, Yamchi MR, Baradaran B, Jafarabadi MA (2019) Induction of apoptosis by a combination of 2-deoxyglucose and metformin in esophageal squamous cell carcinoma by targeting cancer cell metabolism. Iran J Med Sci 44(2):99PubMed

126.

He Y, Tan X, Hu H, Wang Q, Hu X, Cai X, Guan Y, Chen B, Jing X (2018) Metformin inhibits the migration and invasion of esophageal squamous cell carcinoma cells by downregulating the protein kinase B signaling pathway. Oncol Lett 15(3):2939–2945PubMed

127.

Liang F, Wang Y-G, Wang C (2018) Metformin inhibited growth, invasion and metastasis of esophageal squamous cell carcinoma in vitro and in vivo. Cell Physiol Biochem 51(3):1276–1286PubMedCrossRef

128.

Ye J, Chen K, Qi L, Li R, Tang H, Zhou C, Zhai W (2018) Metformin suppresses hypoxia-induced migration via the HIF-1α/VEGF pathway in gallbladder cancer in vitro and in vivo. Oncol Rep 40(6):3501–3510PubMed

129.

Bi T, Zhu A, Yang X, Qiao H, Tang J, Liu Y, Lv R (2018) Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway. Cytotechnology 70(1):439–448PubMedCrossRef

130.

Yamashita T, Kato K, Fujihara S, Iwama H, Morishita A, Yamana H, Kobayashi K, Kamada H, Chiyo T, Kobara H (2020) Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. Anticancer Drugs 31(3):231–240PubMedCrossRef

131.

Lee J, Hong EM, Kim JH, Jung JH, Park SW, Koh DH, Choi MH, Jang HJ, Kae SH (2019) Metformin induces apoptosis and inhibits proliferation through the AMP-activated protein kinase and insulin-like growth factor 1 receptor pathways in the bile duct cancer cells. J Cancer 10(7):1734PubMedPubMedCentralCrossRef

Titel: Anticancer potential of metformin: focusing on gastrointestinal cancers
verfasst von: Mohammad rafi Khezri
Hassan Malekinejad
Naime Majidi-Zolbanin
Morteza Ghasemnejad-Berenji
Publikationsdatum: 20.03.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2021
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-021-04256-8

Springer Medizin

Anticancer potential of metformin: focusing on gastrointestinal cancers

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)

Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie